| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424529000 | Blood | 73 |
| 20130078311 | COMPOSITION FOR TREATING AND/OR PREVENTING OSTEOPOROSIS - The invention relates to a composition comprising deer velvet antler blood (DVAB) in combination with velvet antler for use in the treatment and/or prevention of osteoporosis and a method for treating and/or preventing osteoporosis, comprising administering a therapeutically effective amount of a composition comprising DVAB and velvet antler to a subject at risk of developing or afflicted with osteoporosis. The composition of the invention, when administered to a subject with osteoporosis, increases anti-osteoporotic activity, decreases the biomarker of osteoporosis and recovers the biomechanical strength and structure of bone, suggesting that the said composition could significantly prevent and even treat osteoporosis. | 03-28-2013 |
| 20080268064 | METHOD FOR TREATING CARTILAGE DEFECTS - Methods for treating a cartilage defect comprising fractioning blood to produce a blood component, shaping the cartilage defect to expose subchondral bone, microfracturing the subchondral bone, and applying the blood component to the microfractured subchondral bone. The blood component can comprise platelet-poor plasma. | 10-30-2008 |
| 20130078312 | Biodegradable Putty Compositions and Implant Devices, Methods, and Kits Relating to the Same - Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant. | 03-28-2013 |
| 20100112080 | MULTIMERIC Fc RECEPTOR POLYPEPTIDES INCLUDING A MODIFIED Fc DOMAIN - A soluble multimeric polypeptide or protein is disclosed that is able to inhibit interaction of leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more Fc binding regions linked in a head to tail arrangement, at least one of which is derived from an FcγR type receptor, and an Fc domain of an immunoglobulin which has been modified to reduce or prevent binding to the said Fc binding regions and/or to alter effector function. Also described are polynucleotide molecules encoding the polypeptide or protein and the use thereof in methods of treating a subject for an immune-complex (IC)-mediated inflammatory disease. | 05-06-2010 |
| 20090011043 | TISSUE SEALANT MADE FROM WHOLE BLOOD - Disclosed are tissue sealants that include whole blood and an effective amount of an exogenous protein cross-linker to cross-link the whole blood. Also disclosed are methods for forming a tissue sealant. Such methods include, providing whole blood and mixing the whole blood with an effective amount of an exogenous protein cross-linker to cross-link the whole blood into an adherent mass, thereby forming the tissue sealant. The disclosed tissue sealants can be used for any application, for example to achieve hemostasis, bond tissue of a subject and/or or seal a fluid or gas leak in a tissue of a subject. | 01-08-2009 |
| 20100266707 | METHOD OF TREATING CACHEXIA WITH THE REMOVAL OR INACTIVATION OF MACROPHAGE INHIBITORY CYTOKINE-1 - A method of treating cachexia is disclosed involving the removal or inactivation of macrophage inhibitory cytokine-1 (MIC-1) present in the blood, plasma or serum of a cachexia subject. In one embodiment, the method comprises the steps of providing a suitable substrate for binding MIC-1 (e.g. a substrate provided with a MIC-1 binding molecule), treating blood, plasma or serum removed from a subject by contacting the blood, plasma or serum ex vivo with the substrate such that MIC-1 present in the blood, plasma or serum is bound to the substrate, separating the treated blood, plasma or serum from the substrate, and thereafter returning the treated blood, plasma or serum to the subject. Also disclosed, is a method of diagnosing or prognosing cachexia in a subject, said method comprising determining the amount of MIC-1 present in the subject. | 10-21-2010 |
| 20090263492 | Diagnostic Methods and Genetic Markers for Alzheimer Disease - Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases. | 10-22-2009 |
| 20080279956 | Method for collecting a live placenta cord stem cell - The present invention discloses a method for collecting a live placenta cord stem cell, in which the live placenta cord stem cells are required to be healthy and plenty of endocrine. The cord is first picked with a proper length, then dipped in the sodium citrate solution of a specific concentration as an anticoagulant and then preserved in a refrigerator to maintain natural activity thereof. The collected stem cells can be implanted into human bodies without synthetic chemicals, side effects and rejection, and therefore are suitable for treating many diseases. | 11-13-2008 |
| 20090311338 | CROSSLINKING METHODS AND APPLICATIONS THEREOF - Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum. | 12-17-2009 |
| 20090136586 | Method for Extracorporeal Removal of a Pathogenic Microbe, an Inflammatory Cell or an Inflammatory Protein From Blood - The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein/and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein. | 05-28-2009 |
| 20120195969 | TREATMENT OF ACNE BY CONDITIONED MEDIA - Disclosed are methods and compositions for treatment of acne or acneform conditions, particularly but not limited to, acne vulgaris with products generated from culture of stem or progenitor cells. Specifically, compositions of matter are disclosed which are useful for the treatment of acne and acne associated disease states, in particular acne vulgaris, by topical administration of products derived from stem cells or progenitor cells. | 08-02-2012 |
| 20110111048 | PRODUCING METHOD FOR LIVING ORGANISM-APPLICABLE HYDROGEN-CONTAINED FLUID AND PRODUCING APPARATUS FOR THE SAME - A producing method for a living organism-applicable hydrogen-contained fluid, which includes hydrogen molecules in living organism-applicable fluid enclosed in a container ( | 05-12-2011 |
| 20110033554 | Method of Viral Inactivation of Biological Fluids - The invention relates to a novel method of virally inactivating biological fluids by solvent/detergent treatment of the fluid, followed by oil extraction and filtration. | 02-10-2011 |
| 20110250287 | One step removal of selected molecules from body fluid and tissue - A method for reducing the number of selected antibodies in a subject's blood, the method comprising removing blood from the subject, passing the blood along an enclosed pathway, wherein the pathway comprises one or more semi-permeable hollow fibers with one or more membranes having surfaces positioned substantially perpendicular to the length of the one or more hollow fiber and antigens specific for the antibodies immobilized on the one or more membranes, returning the treated blood to the internal circulation of the subject, wherein the returned treated blood has a reduced number of selected antibodies compared to before treatment. | 10-13-2011 |
| 20120121720 | Modulation of Beta 2 Adrenergic Receptors by Inhibitors of EGLN3 or pVHL - This present invention relates to methods, compositions, and kits useful for treating a patient having or at risk for developing a disorder associated with decreased expression of β2 adrenergic receptors or need for increased 132 adrenergic receptor activity. | 05-17-2012 |
| 20080199532 | Long Lasting Natriuretic Peptide Derivatives - This invention relates to long lasting natriuretic peptide (NP) derivatives. The NP derivative has a NP peptide and a reactive entity coupled to the NP peptide. The reactive entity is able to covalently bond with a functionality on a blood component. In particular, this invention relates to NP derivatives having an extended in vivo half-life, and method for the treatment of cardio-vascular diseases and disorders such as acute decompensated congestive heart failure (CHF) and chronic CHF. | 08-21-2008 |
| 20110027380 | CARBON DIOXIDE REMOVAL FROM WHOLE BLOOD BY PHOTOLYTIC ACTIVATION - Apparatus and methods for removing carbon dioxide from whole blood. Hydrogen ions are generated from water in the blood, resulting in the formation and release of carbon dioxide from the blood. | 02-03-2011 |
| 20100159022 | BONE INDUCTION SYSTEM AND METHODS - An osteogenic composition suitable for use in bone and soft tissue reparative procedures is provided for herein. Methods for preparing osteogenic composition from blood and bone marrow are also provided for. The osteogenic compositions contain therapeutically effective concentrations of one or more osteogenic agents such as BMP-2, TGF-β, PDGF and VEGF. | 06-24-2010 |
| 20080220083 | Pharmaceutical Agent Comprising Blood Components <10 Kda And Their Use For Prophylaxis And Treatment Of Defects Of The Immune System - The invention relates to a composition of proteins, peptides and/or peptide components, a pharmaceutical agent comprising said composition, a method for the production of said composition and the use thereof in the prophylaxis or therapy of persons, animals and/or patients with pathogenic modifications and/or cellular immunodeficiencies, especially cancer, septicemia or allergic reactions, in connection with a cytostatic agent therapy, chemotherapy and/or radiotherapy. | 09-11-2008 |
| 20120003323 | EYE DROPS CONTAINING A DEPROTEINIZED CALF BLOOD EXTRACT - The present invention provides an eye drops, containing an therapeutically effective amount of the deproteinized calf blood extract, chitosan oligosaccharide, and water. The eye drops of the present invention is stable, and can be used for the treatment of pathological changes of cornea and conjunctiva as well as xerophthalmia. | 01-05-2012 |
| 20100183735 | METHOD FOR INDUCING SELECTIVELY SUPPRESSED IMMUNE RESPONSE TO TRANSPLANTED TISSUE OR CELLS - Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor. In a second embodiment, dendritic cells loaded with tumor antigens are injected intradermally to monitor the anti-cancer immunity induced by Transimmunization. | 07-22-2010 |
| 20090017128 | CARBON DIOXIDE REMOVAL FROM WHOLE BLOOD BY PHOTOLYTIC ACTIVATION - Apparatus and methods for removing carbon dioxide from whole blood. Hydrogen ions are generated from water in the blood, resulting in the formation and release of carbon dioxide from the blood. | 01-15-2009 |
| 20120321721 | NOVEL FORMULATION OF PHYSIOLOGICAL CHITOSAN-INORGANIC SALT SOLUTION/BLOOD MIXTURES FOR TISSUE REPAIR - The present description relates to a polymer composition for use in repairing tissue of a patient comprising at least one blood component, a polymer, such as chitosan, and at least one inorganic salt, such as NaCl, method of using the composition and method of preparing the composition. | 12-20-2012 |
| 20120087987 | COMBINED USE OF TWO INSECTICIDES - The present disclosure relates to the combined use of two pesticides. A first pesticide composition provides an initial contact kill, and may form a barrier when applied to greasy surfaces. A second pesticide composition provides residual pesticidal activity on the surface. Methods of making and using the pesticide compositions are also provided. | 04-12-2012 |
| 424530000 | Plasma | 34 |
| 20080305178 | USE OF A HIGH MOLECULAR WEIGHT EXTRACELLULAR HAEMOGLOBIN AS A BLOOD SUBSTITUTE - A blood substitute, of an extracellular haemoglobin having a molecular weight of approximately 3 to approximately 4 million daltons, comp sing chains of polymerised globins, containing free cysteines capable of binding to NO and/or SNO groups, and having a P | 12-11-2008 |
| 20100112081 | USE OF PLATELET RICH PLASMA COMPOSITION IN THE TREATMENT OF CARDIAC CONDUCTION ABNORMALITIES - Methods and kits for treating a cardiac arrhythmia using a platelet rich plasma (PRP) composition are provided. Any type of arrhythmia may be treated using the PRP composition. The PRP composition may comprise PRP developed using blood collected from a patient suffering the cardiac arrhythmia. The PRP composition may be buffered to a physiological pH and may include one or more anti-arrhythmic agents, anti-coagulants, or other drugs. The PRP composition may be delivered using a nebulizer, minimally invasively, or surgically. In some embodiments, the PRP composition may be coated on one or more medical devices. The PRP composition may be delivered to an identified portion of the electrical conduction system of the heart affected and/or causing the arrhythmia to occur. | 05-06-2010 |
| 20130045279 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION - The present invention discloses a composition that contains (1) an effective amount of an analgesically and/or anti-inflammatory active fraction separated from a mixture of plasma and/or serum, and (2) at least one metal, metal ion or metal salt, in which the mixture has been denatured. Also disclosed are methods of producing the composition for treating a subject afflicted with inflammation and/or pain. | 02-21-2013 |
| 20130028980 | CELL-POLYMER FIBER COMPOSITIONS AND USES THEREOF - The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-β-1→4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis. | 01-31-2013 |
| 20090092679 | PARTICLE/CELL SEPARATION DEVICE AND COMPOSITIONS - A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted. | 04-09-2009 |
| 20090092678 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 04-09-2009 |
| 20130122107 | Freeze-Dried Plasma Formats for the Trauma Care Field - Disclosed are freeze-dried plasma formats specifically designed for the trauma care field. Blood plasma is subjected to a glucose removal step, a protein fraction up-concentration step and addition of stabilizers prior to freeze-drying. Preferable stabilizers are glutamine dipeptides, glutamine and glycine. The glutamine based formulation is added direct to plasma and serves three main purposes: 1) Increases stability of plasma proteins and stabilizes pH in freeze-dried state; 2) Increases stability of plasma proteins against Gamma Irradiation and thus allows for the application of a terminal sterilization step; 3) Introduces supplements beneficial to the trauma patient. | 05-16-2013 |
| 20110104298 | Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma - A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized in that | 05-05-2011 |
| 20080286379 | Method and Means for Obtaining Platelet-Rich Plasma - Method and means for obtaining thrombocyte-rich plasma (platelet-rich plasma, PRP) from whole blood which specifically has a high content of specifically activated thrombocytes and which is particularly easy to coagulate. | 11-20-2008 |
| 20100285146 | PEPTIDES AND METHODS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS - A method is disclosed for treating systemic lupus erythematosus in a mammalian subject, comprising administering to said subject an effective dose of at least one laminin peptide, or an analog or a derivative thereof. In one exemplary embodiment, the laminin peptide is selected from the group consisting of R38 (SEQ. ID. NO. 1), and claimed R38 analogs and derivatives thereof including 5200 (SEQ. ID. NO. 10), 5104 (SEQ. ID. NO. 15), 5105 (SEQ. ID. NO. 16), 5106 (SEQ. ID. NO. 17), 5107 (SEQ. ID. NO. 18), 5108 (SEQ. ID. NO. 19), 5109 (SEQ. ID. NO. 20), 5110 (SEQ. ID. NO. 21). The laminin peptides of the present invention may be prepared by known chemical synthetic methods or by biotechnological methods. The invention also provides assays useful for the diagnosis of and following pathological activity course of systemic lupus erythematosus in patients suffering therefrom. In addition, the subject invention concerns a method of treating systemic lupus erythematosus in a subject comprising the extracorporeal removal of lupus antibodies from the subject's plasma and returning the plasma to the subject. In an additional aspect, the invention provides method of reducing anti-R38 antibody levels in a patient's plasma. | 11-11-2010 |
| 20120141593 | METHODS OF INCREASING PRODUCTIVITY IN OLDER SOWS WHILE DECREASING FEED INTAKE - The present invention provides methods for feeding older sows that beneficially reduce feed intake in older sows, yet improve pig survival and weaning weight of pigs from older sows. | 06-07-2012 |
| 20110111049 | Ischemia/reperfusion protection compositions and methods of using - The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery. | 05-12-2011 |
| 20110008458 | Process for removing growth factors from platelets - A sub-atmospheric, negative pressure is applied to a growth factor starting material, such as whole blood, to release growth factors and plasma in a non-destructive medium. The released growth factors having a weight of about 70-76 kDaltons are applied in either a filtered or unfiltered state to a wound to promote healing of the wound. The released growth factors are applied topically to the area of a surface wound to effect healing. The released growth factors are also injected into soft tissue, such as a torn tendon, to promote tissue growth and healing. The growth factors are released in one method from a patient's own blood. In another method the growth factors are released from a whole blood source and freeze dried by conventional lyophilization. Then at a later date, the freeze dried product is reconstituted by normal saline for treatment of a patient's wound or for use in a surgical procedure. | 01-13-2011 |
| 20110008459 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 01-13-2011 |
| 20120201896 | BIOLOGIC REPLACEMENT FOR FIBRIN CLOT - The invention provides composition and methods for repairing a ruptured anterior cruciate ligament. | 08-09-2012 |
| 20090317483 | Bicomponent Bioadhesive for Biomedical Use - The invention relates to new biocomponent bioadhesive formulations, with a synthetic part and an autologous biological part of blood origin comprising plasma rich in platelets and in growth factors, and its use of same in biomedicine, preferably in opththalmic surgery. | 12-24-2009 |
| 20090136587 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NERVE DAMAGE COMPRISING BLOOD PLASMA OR SERUM - The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete structural continuity in the spinal nerve lesion sites. Thus, the composition is useful for the treatment of nerve damage. | 05-28-2009 |
| 20120201897 | COMPOSITION FOR INDUCING TISSUE REGENERATION BY ACTIVATING PLATELET-RICH PLASMA (PRP), AND METHOD FOR MANUFACTURING SAME - The present invention relates to a composition for cartilaginous tissue repair and to a production method therefor. The present invention comprises the steps of: (a) dissolving freeze-dried fibrinogen in an aprotinin solution; (b) dissolving freeze-dried thrombin in a stabilizing solution; (c) mixing an enriched collagen solution with thrombin and the stabilizing solution; and installing the fibrinogen solution (a) to one side of a dual kit and the solution (c) containing the collagen to the other side, and then mixing and injecting into damaged cartilaginous tissue. In the present invention, which is constituted as described above, biomaterials such as collagen and fibrin are mixed so as to allow damaged cartilaginous tissue to be repaired to a state allowing transplantation onto the tissue, and efficient regeneration is induced, thereby making it possible to reduce surgery-related stress on people and animals while inducing relatively rapid and efficient cartilage repair and regeneration. | 08-09-2012 |
| 20100323029 | FIVE-COORDINATE NEUROGLOBIN AND USE THEREOF AS A BLOOD SUBSTITUTE - Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood. | 12-23-2010 |
| 20100159023 | METHOD FOR STABILISING BLOOD PLASMA COMPONENTS IN A LYOPHILISATE - Process for the stabilization of blood plasma components in a lyophilizate, wherein
| 06-24-2010 |
| 20090196938 | USE OF A MATRIX FOR REMOVING C-REACTIVE PROTEIN FROM BIOLOGICAL FLUIDS - The present invention relates to a method for treating the risk of increased C-reactive protein (CRP) levels by conducting extracorporeal perfusion of blood plasma from patients with risk for cardiovascular diseases or immune dysfunctions, such as autoimmune diseases, through a device, such as a column, which contains absorbent matrix material including lipids, peptides, polypeptides, phosphocholine (PC) or PC derivatives so as to remove C-reactive protein. Moreover, the present invention relates to the use of compounds which have the characteristic to bind CRP at least temporarily, for removing CRP from biological fluids of a patient for prophylaxis and/or treatment of autoimmune diseases, cardiovascular diseases, such as infarction, stroke, diabetes, rheuma and renal failure. | 08-06-2009 |
| 20100189802 | Method for treatment of vascular hyperpermeability - A method comprising preparing a vascular hyperpermeability treatment composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof in a form deliverable to a mammal; whereby an effective amount of the composition raises the threshold for apoptosis and/or prevents or lessens the occurrence of vascular hyperpermeability. A method comprising preventing hyperpermeability associated with hemorrhagic shock via preparing a composition in a form deliverable to a mammal, the composition comprising an apoptosis regulating protein, a antioxidant, a mitochondrial modulator, a biological effector molecule, or combinations thereof; and raising the threshold for apoptosis in a mammal's endothelial cells by administering an effective amount of said antioxidant; whereby said raising the threshold for apoptosis prevents said hyperpermeability. | 07-29-2010 |
| 20120045518 | ENHANCING COAGULATION OR REDUCING FIBRINOLYSIS - Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma). | 02-23-2012 |
| 20120003324 | Methods and Apparatus for Manufacturing Plasma Based Plastics and Bioplastics Produced Therefrom - Blood-derived plastic articles prepared from compositions including blood and, in some embodiments, at least one crosslinking agent and/or at least one biological response modifier, that can be useful for biological applications such as wound repair and tissue grafts; methods of making and using the same; methods for assessing the concentration of a biological response modifier in an article; and systems for preparing blood-derived plastic articles are provided. | 01-05-2012 |
| 20100196497 | Method of Treating Tissue Using Platelet-Rich Plasma in Combination with Low-Level Laser Therapy - This invention is a method of treating a patient's injured tissue by applying platelet-rich plasma and laser energy to the injured tissue. The applied energy is low-level, and the patient feels no sensation of the low-level laser energy being applied. The laser energy can be applied before, after, or during the platelet-rich plasma application, or any combination thereof. Additional laser therapy may be applied over the entire extremity containing the injury, any non-injured adjacent tissue, as well as to the patient's entire body for stimulation of other body systems. Additionally, laser energy can be applied to the platelet-rich plasma before the platelet-rich plasma is applied to the patient. | 08-05-2010 |
| 20120114760 | COMPOSITIONS FOR TREATING WOUNDS AND PROCESSES FOR THEIR PREPARATION - Embodiments of the invention are directed to methods of treating a wound by administering a wound-healing composition and the wound-healing composition. The wound-healing composition has a purified platelet-removed platelet-rich plasma and a wound-healing component. The wound-healing component is a protein, a peptide, or combinations thereof. The methods of treatment utilize an amount of the wound-healing composition sufficient to treat a patient with a wound, which may occur by promoting an activity of cell migration, cell proliferation, and/or angiogenesis. Also disclosed are processes for preparing the wound-healing composition. | 05-10-2012 |
| 20120027867 | Spray-Dried Blood Products and Methods of Making Same - The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above. | 02-02-2012 |
| 20080299212 | Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum - The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms by dissolving away hyaline granules in the cornea of a patient with severe Avellino corneal dystrophy due to LASIK surgery. | 12-04-2008 |
| 20120263796 | ANTI-VLA-4 RELATED ASSAYS - Methods and apparatus for assaying the level of analytes in a sample, related to VLA-4, are disclosed. A method of decreasing the level of an anti-integrin antibody in a subject is described including a) contacting a biological sample from a subject with a detectable capture agent associated with a substrate, wherein the capture agent can bind an anti-integrin antibody in the sample; b) detecting binding of the capture agent with the level of the anti-integrin antibody; and c) treating the subject with plasma exchange until the level of the anti-integrin antibody in the sample reaches a predetermined level. | 10-18-2012 |
| 20090035382 | METHOD AND COMPOUND FOR THE TREATMENT OF ARTICULAR DISEASES OR ARTICULAR PAIN, OR FOR THE TREATMENT OF SKIN FOR AESTHETIC OR OTHER PURPOSES, AND THE METHOD OF PREPARATION OF THE COMPOUND - Method for the treatment of articular diseases or articular pain, or for the treatment of skin, which comprises the infiltration or the application of a compound that comprises at least one blood-derived substance, which is preferably a blood plasma in general, and in particular a platelet-rich plasma (PRP), and preferably a plasma rich in growth factors (PRGF), and/or a supernatant of any of the aforementioned plasmas. The inventive method enables the significant relief and even regeneration of the treated areas. Optionally, the blood-derived substance may be mixed with hyaluronic acid (HA) and/or an HA-derived compound, thereby achieving even more beneficial effects. | 02-05-2009 |
| 20100233282 | DEVICE AND METHODS FOR DELIVERY OF BIOACTIVE MATERIALS TO THE RIGHT SIDE OF THE HEART - A method of delivering a bioactive composition to the right side of the heart is described. The method can be used to treat cardiac dysfunction such as myocardial infarction, arrhythmias or congestive heart failure. A dual lumen catheter is described for delivering the bioactive substance by inserting a first cannula of a dual lumen catheter into a vein to access the right ventricle. The first cannula has a first balloon which is blown up proximal to the tricuspid valve. A second cannula is then introduced which accesses the right side of the heart and coronary sinus. The bioactive substance is then delivered to the right side of the heart. The bioactive substance may include platelets and/or white blood cells at concentrations higher than what is normally found in whole blood. | 09-16-2010 |
| 20120087989 | USE OF GELLED PRP (PLATELET GEL) FOR VOLUMETRIC BREAST RECONSTRUCTION - The present invention relates to the application of a platelet gel for augmenting or restoring the volume of a soft tissue, particularly breast tissue, to biological implants comprising said gel, to a kit for preparing said implants and to a process for preparing said implants. | 04-12-2012 |
| 20120087988 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY CONDITIONS USING PLATELET ENRICHED PLASMA - Described herein are methods and compositions for the treatment of respiratory diseases such as, for example, exercise induced pulmonary hemorrhage. The methods include the use of compositions comprising platelet enriched plasma, for example, platelet rich plasma and/or platelet poor plasma, for treatment of respiratory diseases in humans and animals, in particular, equines, by administration to the respiratory system. | 04-12-2012 |
| 20110280952 | Platelet Lysate and Bioadhesive Compositions Thereof for the Treatment of Mucositis - The present invention concerns the use of platelet lysate for treating and/or preventing mucositis. Moreover, a mucoadhesive composition comprising such a platelet lysate for the therapy and/or prevention of mucositis and of corneal lesions is described. | 11-17-2011 |
| 424531000 | Serum | 5 |
| 20130039991 | Elimination of N-Glycolylneuraminic Acid From Animal Products For Human Use - The application is in the field of transgenic (non-human) organisms, sialic acid chemistry, metabolism and antigenicity. More particularly, the invention is related to a method to produce Neu5Gc-free animals and products therefrom comprising disrupting the CMAH gene and thereby reducing or eliminating Neu5Gc from biological material of non-humans. | 02-14-2013 |
| 20100112082 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 05-06-2010 |
| 20120294951 | USE OF GOAT SERUM FOR VETERINARY TREATMENT - Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses. | 11-22-2012 |
| 20110244053 | Use a goat serum for veterinary treatment - Methods for veterinary treatment of mammals are described, for treatment of conditions having an inflammatory component. The methods are particularly suited to treatment of cats, dogs, or horses. | 10-06-2011 |
| 20110318424 | METHODS FOR PROLONGING VIABILITY OF CONE CELLS USING MODULATORS OF THE MAMMALIAN TARGET OF RAPAMYCINE (mTOR) - The present invention is directed to the use of modulators of the mammalian target of rapamycine (mTOR) pathway, glucose and/or glucose enhancers for treating retinal disorders and, in particular, for prolonging the viability of cone cells. | 12-29-2011 |
| 424532000 | Platelet | 8 |
| 20130084341 | Compositions and Methods to Promote Implantation and Engrafment of Stem Cells - Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells. | 04-04-2013 |
| 20100178355 | METHOD FOR IN SITU SOLIDIFICATION OF BLOOD-POLYMER COMPOSITIONS FOR REGENERATIVE MEDICINE AND CARTILAGE REPAIR APPLICATIONS - The present invention relates to a method for repairing or regenerating tissues in a patient such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, cardiac tissues and ulcers. The method comprises the step of administering simultaneously or sequentially a pro-coagulant factor and an effective amount of a polymer composition comprising a biocompatible polymer and blood or a component thereof. When the polymer composition is in contact with the pro-coagulant factor it is converted into a non-liquid state such that the polymer composition will adhere to the site in need of repair to effect repair of the tissue and/or regeneration thereof. | 07-15-2010 |
| 20100316727 | TREATMENT OF INFLAMMATORY DISORDERS WITH OZONE - Methods for therapeutic treatment of inflammatory conditions in a mammalian patient provide clinical benefits including reduction of inflammation, vasorelaxation, reduction in edema and increased blood flow, the methods generally comprising extracorporeal treatment of blood, blood fractionate, or other biological fluid to expose such fluids to a precise, measured amount of ozone to produce a blood or biological fluid having a quantified absorbed dose of ozone, and reinfusing the treated biological fluid to the patient to provide therapeutic effects beneficial in the treatment of inflammatory disorders and related symptoms or conditions. | 12-16-2010 |
| 20120114761 | SKINCARE STIMULANT HAVING A PLATELET DRY POWDER - A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, wherein the effective dose refers to the presence of at least 1000 platelets in every milligram of skincare stimulant. | 05-10-2012 |
| 20120156306 | VIRAL INACTIVATED PLATELET EXTRACT, USE AND PREPARATION THEREOF - The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. | 06-21-2012 |
| 20120315338 | LARGE SCALE GENERATION OF FUNCTIONAL MEGAKARYOCYTES AND PLATELETS FROM HUMAN EMBRYONIC STEM CELLS UNDER STROMAL-FREE CONDITIONS - The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion. | 12-13-2012 |
| 20120321722 | Platelet Storage and Reduced Bacterial Proliferation In Platelet Products Using A Sialidase Inhibitor - The present invention relates to methods and compositions for reducing sialidase activity and inhibiting bacterial proliferation of one or more bacteria in a platelet product preparation from one or more donors. In general, the method includes contacting the platelet product preparation with an amount of a sialidase inhibitor, to thereby obtain a sialidase inhibitor-treated platelet product preparation. Sialidase activity is reduced and the proliferation of one or more bacteria is inhibited, as compared to a platelet product preparation not subjected to the sialidase inhibitor treatment. | 12-20-2012 |
| 20120093941 | NEUTROPHIL-DEPLETED PLATELET RICH PLASMA FORMULATIONS FOR CARDIAC TREATMENTS - Compositions and methods for preparing neutrophil-depleted platelet rich plasma are provided. Generally, these compositions comprise a higher concentration of platelets and depressed concentrations of neutrophils relative to whole blood although white blood cells may be at higher concentrations than whole blood. The concentrations of the platelets and/or the white blood cells may be two to eight times the respective concentrations in whole blood. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The neutrophil-depleted platelet rich plasma composition may be delivered in conjunction with reperfusion therapy. | 04-19-2012 |
| 424533000 | Erythrocyte | 1 |
| 20090155376 | PROTEIN HYDROLYSATE WITH ANTIDIABETIC EFFECT - The present invention provides compositions (blood sugar increase inhibitors) that have an action of lowering the blood sugar level of a subject in a hyperglycemic condition and are for use in lowering the blood sugar level of such a subject. Moreover, the present invention provides compositions for use in preventing or treating diseases resulting from hyperglycemia, in particular, diabetes and diabetic complications, due to the aforementioned action (a preventive or ameliorative composition for diseases resulting from hyperglycemia, an antidiabetic agent). | 06-18-2009 |
| 424534000 | Leucocyte | 1 |
| 20120015040 | Dendritic Cell Precursor Populations, Dendritic Cell Populations Derived Therefrom and Uses Thereof - Dendritic cell precursor populations, dendritic cell populations derived therefrom, methods for isolating, expanding and using are disclosed. | 01-19-2012 |
